^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H3-targeted antibody-drug conjugate

    Related drugs:
    1d
    A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001) (clinicaltrials.gov)
    P1/2, N=232, Active, not recruiting, Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    Tecentriq (atezolizumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    4d
    Phase I/II clinical study of SYS6043 combined with PD-1/PD-L1 inhibitor ± chemotherapy in the treatment of advanced solid tumor participants (ChiCTR2500112838)
    P1/2, N=622, Not yet recruiting, Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
    New P1/2 trial
    |
    cisplatin • carboplatin • gemcitabine • Tevimbra (tislelizumab-jsgr) • pemetrexed • etoposide IV • Hetronifly (serplulimab) • Enshuxing (enlonstobart)
    8d
    A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=736, Not yet recruiting, BioNTech SE
    New P3 trial
    |
    docetaxel • prednisone • BNT324
    18d
    Evaluation of the Effect of Itraconazole on the Pharmacokinetics of HS-20093 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=18, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting | Trial primary completion date: Dec 2025 --> Jul 2026
    Enrollment open • Trial primary completion date
    |
    itraconazole • risvutatug rezetecan (GSK5764227)
    26d
    The investigational anti-B7-H3 antibody-drug conjugate vobramitamab duocarmazine exerts anti-tumor activity in vitro and in vivo in pediatric sarcoma preclinical models. (PubMed, Cell Death Dis)
    Repeated vobra duo doses ameliorated this outcome, reverting rhabdomyosarcorma to rhabdomyoma tumor, by increasing Desmin and Myogenin/Myf-4 differentiation markers expression, and reducing both Ki-67 and CD133. In conclusion, the in vitro and in vivo anti-tumor effects towards pSC highlight the need to extend the investigation to patient-derived preclinical models, to pave the way for clinical translation.
    Preclinical • Journal
    |
    CD276 (CD276 Molecule) • CASP3 (Caspase 3) • EIF4EBP1 (Eukaryotic translation initiation factor 4E binding protein 1)
    |
    vobramitamab duocarmazine (MGC018)
    27d
    A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=84, Recruiting, GlaxoSmithKline | Phase classification: P1/2 --> P1 | Not yet recruiting --> Recruiting
    Enrollment open • Phase classification
    |
    Avastin (bevacizumab) • 5-fluorouracil • Xtandi (enzalutamide) • leucovorin calcium • risvutatug rezetecan (GSK5764227)
    29d
    GenSci143 in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=180, Recruiting, Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    1m
    SKB500 Combinations in Patients With Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
    New P2 trial
    |
    carboplatin • etoposide IV
    2ms
    A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101) (clinicaltrials.gov)
    P1, N=590, Recruiting, GlaxoSmithKline | N=316 --> 590
    Enrollment change • Pan tumor
    |
    Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • Tecentriq (atezolizumab) • carboplatin • Imfinzi (durvalumab) • risvutatug rezetecan (GSK5764227)
    2ms
    A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=72, Not yet recruiting, GlaxoSmithKline
    New P1/2 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • Xtandi (enzalutamide) • leucovorin calcium • risvutatug rezetecan (GSK5764227)
    2ms
    A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and/or Refractory Solid Tumors (clinicaltrials.gov)
    P1, N=168, Completed, AbbVie | Active, not recruiting --> Completed | Trial completion date: Jun 2025 --> Sep 2025 | Trial primary completion date: Jun 2025 --> Sep 2025
    Trial completion • Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • HER-2 positive • EGFR mutation • HR positive • BRAF mutation • HER-2 negative • ALK mutation • ROS1 positive • HR positive + HER-2 negative
    |
    paclitaxel • docetaxel • mirzotamab clezutoclax (ABBV-155)
    2ms
    Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer (clinicaltrials.gov)
    P1, N=63, Recruiting, Hansoh BioMedical R&D Company | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HRS-5041 • risvutatug rezetecan (GSK5764227)